Nikhil Lalwani sold $1.9M of ANIP
PRESIDENT & CEO at ANI PHARMACEUTICALS INC. 33,481 shares at an average of $57.99, traded Nov 26, 2024, filed Nov 27, 2024.
Score components
- +25RoleCEO
- +25Trade size$1.9M at market
- 0Share of holdings soldSold 8.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.4%, 3m -7.4%, 6m -2.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001822629-24-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2024 | MOption exercise Common Stock | +30,000 | $29.00 | $870k | 403,859 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -30,000 | $57.95 | $1.7M | 373,859 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -3,481 | $58.30 | $203k | 370,378 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Stock Option (right to buy)derivative | -30,000 | $29.00 | $870k | 138,027 | Nov 27, 2024 |
Related signals
Other insiders at ANI PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $208k 2,850 shares | -2% | |
| 36Weak | ANI PHARMACEUTICALS INC | Nikhil Lalwani PRESIDENT & CEO | $383k 5,400 shares | -2% | |
| 18Weak | ANI PHARMACEUTICALS INC | Jeanne Thoma director | $72k 1,000 shares | -4% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $35k 500 shares | -1% | |
| 29Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $207k 2,850 shares | -2% | |
| 36Weak | ANI PHARMACEUTICALS INC | Nikhil Lalwani PRESIDENT & CEO | $401k 5,400 shares | -2% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $38k 500 shares | -1% | |
| 43Moderate | ANI PHARMACEUTICALS INC | Ori Gutwerg SVP, GENERICS | $243k 3,162 shares | -4% | |
| 23Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $232k 2,850 shares | -2% | |
| 9Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $41k 500 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.